Table 5.

All cause morality and cause specific mortality in EGID patients compared to siblings

Outcome	Siblings	EGID
All-cause Death
N	2785*	1513*
Events	150	93
Person-years (*1000)	28.01	14.94
IR (%) [95% CI]	5.36 [4.53–6.28]	6.23 [5.03–7.63]
IR diff. [95% CI]	0 (ref.)	0.87 [-0.66–2.4]
Model 1 aHR [95% CI]	1 (ref.)	1.31 [0.98–1.75]
Model 2 aHR [95% CI]	1 (ref.)	1.26 [0.93–1.70]
Cardiovascular Death
N	2778	1509
Events	32	19
Person-years (*1000)	28	14.93
IR (%) [95% CI]	1.14 [0.78–1.61]	1.27 [0.77–1.99]
IR diff. [95% CI]	0 (ref.)	0.13 [-0.57–0.83]
Model 1 aHR [95% CI]	1 (ref.)	0.87 [0.40–1.89]
Model 2 aHR [95% CI]	1 (ref.)	0.94 [0.42–2.09]
Cancer Death
N	2778	1509
Events	64	40
Person-years (*1000)	28	14.93
IR (%) [95% CI]	2.29 [1.76–2.92]	2.68 [1.91–3.65]
IR diff. [95% CI]	0 (ref.)	0.39 [-0.61–1.39]
Model 1 aHR [95% CI]	1 (ref.)	1.43 [0.92–2.22]
Model 2 aHR [95% CI]	1 (ref.)	1.37 [0.87–2.18]
Other Death
N	2778	1509
Events	54	34
Person-years (*1000)	28	14.93
IR (%) [95% CI]	1.93 [1.45–2.52]	2.28 [1.58–3.18]
IR diff. [95% CI]	0 (ref.)	0.35 [-0.57–1.27]
Model 1 aHR [95% CI]	1 (ref.)	1.39 [0.87–2.22]
Model 2 aHR [95% CI]	1 (ref.)	1.32 [0.80–2.19]

EGID eosinophilic gastrointestinal disorders distal to the esophagus, IR incidence rate, aHR adjusted hazard ratios

Model 1 adjusts for age at EGID diagnosis (first biopsy), sex, county of residence, and calendar year. Model 2 adds adjustments for education, eczema, allergy, asthma, and eosinophilic esophagitis

^*The number of study participants was slightly higher in the overall mortality than in the cause-specific mortality analyses. The follow-up of the cause-specific mortality analyses ended on 31 December 2016 and hence did not include EGID patients diagnosed in 2017 and their controls